Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Jamba, Inc. (JMBA), Medifast Inc (MED), TriMas Corp (TRS): Activist Glenn Welling’s Favorite Picks

Page 1 of 2

In a new filing with the Securities and Exchange Commission, Glenn W. Welling‘s Engaged Capital disclosed raising its stake in Jamba, Inc. (NASDAQ:JMBA) and entering into a stock puchase plan with Mutual Securities, Inc. (MSI). According to the filing, Engaged owns over 1.58 million shares of the company, up from 1.43 million shares held earlier. Following the increase, the activist stake amasses 9.1% of Jamba’s outstanding common stock, versus 8.2% disclosed in a previous filing. Under the terms of the stock purchase plan, MSI will acquire on behalf on Engaged Capital up to around 1.01 million shares of Jamba until May 2016. The plan may be terminated by the fund or it will terminate in case of some special events such as the bankruptcy or insolvency of the company or the acquisition of the company.

Jamba, Inc. (NASDAQ:JMBA)

Engaged Capital’s latest move regarding Jamba, Inc. (NASDAQ:JMBA) preceeds a settlement agreement signed between the investor and the company in January. Under the terms of the agreement, Jamba agreed to appoint Mr. Welling and James C. Papas, a managing member of JCP Investment Management, to its board of directors.

Jamba, Inc. (NASDAQ:JMBA) is a $262.5 million holding company that promotes a healthy and active lifestyle and that operates and franchises Jamba Juice stores, through its subsidiary Jamba Juice Company. Last week, the company released its financial results for the fourth-quarter which showed a loss of $8.0 million, or $0.47 per share, versus a loss of $5.7 million or $0.33 per share a year ago. Even though the company’s net loss widened in year-over-year terms, it still was better than expected. Among the funds that we track, Glenn J. Krevlin‘s Glenhill Advisors is the second-largest shareholder of Jamba, although its stake that consists of 614,000 shares, valued at $9.23 million, amasses only 0.70% of the equity portfolio.

Mr. Welling is an activist investor that manages roughly $122.52 million in an equity portfolio that primarily consists of Services and Technologies stocks. In the majority of companies in which Mr. Welling acquired stakes, he went activist and tried to push for changes that would unlock shareholder value. Last week, the investor initiated a proxy fight against Rovi Corporation (NASDAQ:ROVI), after unsuccessful discussions regarding the company’s strategy and other issues. Therefore, Engaged Capital said in a letter disclosed last week that it had nominated four directors to be elected to the company’s board. Digital television guide provider Rovi hired an adviser to help it fight Engaged Capital, which, according to the company’s claims, tries to seize control of the company. Aside from Jamba, Inc. (NASDAQ:JMBA) and Rovi Corporation, Engaged is also currently pursuing activist campaigns in two other companies: Medifast Inc (NYSE:MED) and TriMas Corp (NASDAQ:TRS), which represent the fund’s second and third-largest holding respectively. The fund also held 4.14 million shares of Silicon Image at the end of 2014, the position being the largest in the fund’s equity portfolio, but the company was acquired by Lattice Semiconductor earlier this year.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!